A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC)
We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin
concurrent chemoradiotherapy as the adjunctive therapy before esophagectomy or as a
definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with
loco-regional esophageal squamous cell carcinoma.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).
Yung-Chie Lee, M.D.
National Taiwan University Hospital
Taiwan: Department of Health